Recent performance snapshot for Quest Diagnostics

Quest Diagnostics (DGX) has drawn investor attention after recent trading, with the stock closing at US$190.85. Short term returns are mixed, with a slight gain over the past week but a decline over the past month.

Over the past 3 months the share price is down about 8%, while the 1 year total return stands at roughly 13%. Year to date, DGX has returned about 10%, supported by annual revenue of US$11.28b and net income of US$1.02b.

This recent pullback, with a 90 day share price return down about 8%, sits alongside a 1 year total shareholder return of roughly 13%. This points to fading short term momentum but a still supportive longer record.

If you are comparing Quest Diagnostics with other healthcare related ideas, it can be helpful to scan for companies using AI in medicine and diagnostics by reviewing 33 healthcare AI stocks

With Quest Diagnostics trading at US$190.85 alongside a reported intrinsic discount of about 40%, the key question now is whether the stock is genuinely undervalued or if the market is already pricing in future growth?

Most Popular Narrative: 14.5% Undervalued

Quest Diagnostics' most followed narrative pegs fair value at $223.25 compared with the latest close at $190.85, which implies meaningful upside in that framework.

Ongoing growth in advanced and preventive testing, including cardiometabolic, autoimmune, brain health, oncology, and women's or reproductive diagnostics, as well as robust demand from functional medicine and wellness focused consumers, are driving higher test volumes and increasing test per requisition, which supports both revenue growth and margin expansion. The accelerating shift toward preventive healthcare and wellness, visible in the expansion of functional medicine and consumer initiated testing, is fueling sustained demand for recurring lab services. This trend underpins expectations for stable, long term top line growth and improved revenue durability.

Curious what sits behind that fair value gap? The narrative leans heavily on recurring test demand, firmer margins, and a richer future earnings multiple. The exact assumptions may surprise you.

Result: Fair Value of $223.25 (UNDERVALUED)

However, that upside story could be challenged if PAMA reimbursement cuts or a heavier tilt toward government and exchange based payers squeeze pricing and margins more than expected.

Next Steps

Mixed messages on value and risks so far? Move quickly, review the details yourself, and weigh both sides by reading 4 key rewards and 1 important warning sign

Ready for more investment ideas?

If Quest Diagnostics interests you, do not stop here. Broader research across sectors and styles can help you spot opportunities others miss.

• Spot potential value plays early by scanning companies trading below their fundamentals with the 47 high quality undervalued stocks
• Strengthen your income watchlist by reviewing stocks that appear built for sustained payouts in the 14 dividend fortresses
• Reduce portfolio stress by focusing on companies with resilient profiles using the 68 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.